Efficacy Study for Treatment of Dementia in Progressive Supranuclear Palsy
NCT ID: NCT00522015
Last Updated: 2008-02-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE2
20 participants
INTERVENTIONAL
2008-02-29
2010-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
1. patients improve and stabilize after 12 -24 week treatment with rivastigmine in memory function
2. use of rivastigmine has a positive effect on apathy in PSP patients
3. therapy with rivastigmine has a no positive benefit on speech and overall results of the MMST
4. changes in motor activity are associated with changes in language and overall results of the in MMST
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
RT001 in Patients With Progressive Supranuclear Palsy (PSP) PROGRESSIVE SUPRANUCLEAR PALSY
NCT04937530
Trial to Evaluate The Efficacy Of Rotigotine on Parkinson's Disease-Associated Motor Symptoms And Apathy
NCT01782222
Cognitive Decline in Non-demented PD
NCT01340885
Efficacy of RIVAstigmine on Motor, Cognitive and Behavioural Impairment in Progressive Supranuclear Palsy
NCT02839642
A Phase 2a Study of TPN-101 in Patients With Progressive Supranuclear Palsy (PSP)
NCT04993768
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
patients take 6 mg rivastigmine daily, if well tolerable increase to 12 mg rivastigmine maximum daily
rivastigmine
rivastigmine 6 mg up to 12 mg daily; Taken in two doses from 3 mg to 6 mg Rivastigmine twice a day
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
rivastigmine
rivastigmine 6 mg up to 12 mg daily; Taken in two doses from 3 mg to 6 mg Rivastigmine twice a day
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* willingness to participate in the study
* informed consent
* ability to speak
* no further CNS diseases
* written informed consent
* stable state of health
* ability to give informed consent, will checked by an independent physician
Exclusion Criteria
* acute psychosis
* pregnancy or lactation
* known previous drug reaction or hypersensitivity of rivastigmine or other carbamate derivatives
* liver failure
* known sick sinus syndrome or excitation disturbance
* known ulcus ventriculi or duodenal ulcer
* known asthma or COPD
* seizures
* renal failure
50 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital Tuebingen
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
University hospital of Tuebingen
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Daniela Berg, Doctor
Role: PRINCIPAL_INVESTIGATOR
University Hospital Tuebingen
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Tuebingen
Tübingen, Baden-Wurttemberg, Germany
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
eudraCT no: 2006-006166-42
Identifier Type: -
Identifier Source: secondary_id
RIVA
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.